• LAST PRICE
    0.9105
  • TODAY'S CHANGE (%)
    Trending Up0.0005 (0.0549%)
  • Bid / Lots
    0.9105/ 10
  • Ask / Lots
    1.0000/ 5
  • Open / Previous Close
    0.9100 / 0.9100
  • Day Range
    Low 0.9100
    High 1.0100
  • 52 Week Range
    Low 0.8100
    High 41.2500
  • Volume
    5,146
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.91
TimeVolumeAXLA
09:32 ET4900.91
09:57 ET3001.01
10:15 ET5001
10:18 ET1160.93
10:29 ET1200.921
11:21 ET10000.9605
12:10 ET3000.921
12:12 ET4580.921
12:46 ET9841
01:38 ET1050.9105
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAXLA
Axcella Health Inc
2.7M
0.0x
---
United StatesZVSA
Zyversa Therapeutics Inc
2.7M
0.0x
---
United StatesIPIX
Innovation Pharmaceuticals Inc
2.7M
-1.1x
---
United StatesPBLA
Panbela Therapeutics Inc
2.6M
0.0x
---
United StatesPHIO
Phio Pharmaceuticals Corp
2.7M
-0.2x
---
United StatesALLR
Allarity Therapeutics Inc
2.6M
0.0x
---
As of 2023-12-06

Company Information

Axcella Health Inc. is a clinical-stage biotechnology company. The Company is focused on a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios with simultaneously impacting multiple biological pathways. Its pipeline includes lead therapeutic candidates for the treatment of Long COVID (also known as Post-COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC)) associated fatigue, and the treatment of non-alcoholic steatohepatitis (NASH). AXA1665 is a product candidate for the reduction in risk of Overt Hepatic Encephalopathy (OHE) recurrence in adult patients with liver cirrhosis. AXA1125 is also being developed as a product candidate for the treatment of Long COVID. AXA1125 is an oral product candidate for the treatment of NASH. AXA1125 is an oral product candidate that contains six amino acids and derivatives.

Contact Information

Headquarters
840 Memorial DrCAMBRIDGE, MA, United States 02139-3789
Phone
617-868-0949
Fax
617-441-6243

Executives

President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Company Secretary, Director
Craig Jalbert

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.7M
Revenue (TTM)
$0.00
Shares Outstanding
2.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.58
EPS
$-19.12
Book Value
$1.41
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.